Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study

Silas Inman @silasinman
Published: Wednesday, Jul 23, 2014

Breast CancerExtended adjuvant treatment with neratinib (PB272, HKI-272) significantly improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab, according to early phase III results released by Puma Biotechnology, the company developing the drug.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication